Search Result

Results for "

FLT3-ITD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (7) AMPK (2) Apoptosis (39) Aurora Kinase (1) Autophagy (3) Bcr-Abl (2) c-Fms (1) c-Kit (8) c-Myc (1) CDK (3) Deubiquitinase (1) Drug Derivative (1) DYRK (1) Epigenetic Reader Domain (1) ERK (6) FGFR (1) FLT3 (62) Haspin Kinase (1) HDAC (4) HSP (1) IRAK (1) JAK (1) Liposome (1) MAP4K (1) MDM-2/p53 (1) MEK (1) MELK (1) Microtubule/Tubulin (1) Mitosis (1) p38 MAPK (2) PDGFR (12) PI3K (1) Pim (2) PROTACs (8) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (3) RET (1) STAT (10) Trk Receptor (1) VEGFR (2)
By Research Areas:	Cancer (72) Cardiovascular Disease (1)
Oligonucleotides:	Liposome (1)

Inhibitors & Agonists

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-172581

Clifutinib	FLT3 Apoptosis Ras p38 MAPK PI3K Akt JAK STAT	Cancer
Clifutinib is an orally active and selective internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) inhibitor with an IC₅₀ value of 15.1 nM. Clifutinib exerts strong antiproliferative effects on FLT3-ITD acute myeloid leukemia (AML) cell lines (MV-4-11: IC₅₀ = 1.5 nM; MOLM-13: IC₅₀ = 1.4 nM). Clifutinib inhibits the activity of FLT3-ITD kinase and blocks the downstream RAS/MAPK, PI3K/AKT, and JAK/STAT5 signaling pathways of FLT3. Clifutinib induces apoptosis of acute myeloid leukemia (AML) cells with FLT3-ITD mutations. Clifutinib demonstrates significant antitumor efficacy in mice bearing MV-4-11 or MOLM-13 xenografts. Clifutinib is promising for research of relapsed/refractory FLT3-ITD-positive acute myeloid leukemia .

HY-124500

AC-4-130 5+ Cited Publications	STAT Apoptosis	Cancer
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .

HY-162037

CDDD11-8	CDK FLT3	Cancer
CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and *FLT3-ITD, with K_i* values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation .

HY-153886

Wu-5 1 Publications Verification	FLT3 AMPK Apoptosis Deubiquitinase	Cancer
Wu-5 is a USP10 inhibitor that can inhibit *FLT3* and AMPK pathways, induce FLT3-ITD degradation and induce apoptosis .

HY-10202

Tandutinib 5 Publications Verification MLN518; CT53518	FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib (MLN518) is a potent and selective inhibitor of the *FLT3* with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier ^[3].

HY-120758

SEL24-B489	Pim FLT3 Apoptosis	Cancer
SEL24-B489 is a potent, type I, orally active, dual PIM and *FLT3-ITD* inhibitor, with K_d values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively .

HY-114323

*PROTAC FLT-3* degrader 1**	PROTACs FLT3 Apoptosis STAT MEK ERK	Cancer
PROTAC FLT-3 degrader 1 is an effective and selective FLT-3 PROTAC degrader with an IC₅₀ of 0.6 nM. PROTAC FLT-3 degrader 1 inhibits both FLT-3 and FLT-3 ITD mutants. PROTAC FLT-3 degrader 1 has the activity of anti-proliferation and induction of apoptosis, which can be used in the study of tumor. (Pink: FLT3 ligand (HY-168702); Black: Linker (HY-124380); Blue: VHL ligand (HY-125845)) .

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual *FLT3* and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-14217

Quizartinib dihydrochloride Maximum Cited Publications 45 Publications Verification AC220 dihydrochloride	FLT3 Apoptosis PDGFR c-Kit	Cancer
Quizartinib (AC220) dihydrochloride is an orally active, potent and selective *FLT3* inhibitor. Quizartinib dihydrochloride inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib dihydrochloride inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib dihydrochloride can be used for the research of cancer .

HY-128572

FLT3-IN-6	FLT3	Cancer
FLT3-IN-6 is a potent and selective inhibitor of *FLT3-ITD* (FLT3 mutation) with an IC₅₀ of 1.336 nM .

HY-100368

MELK-8a 3 Publications Verification NVS-MELK8a	PDGFR Haspin Kinase MELK Mitosis	Cancer
MELK-8a (NVS-MELK8a) is a highly potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor with IC₅₀ of 2 nM. MELK-8a also inhibits Flt3 (ITD), Haspin, PDGFRα with IC₅₀s of 0.18, 0.19, and 0.42 μM, respectively. MELK plays an essential role in regulating cell mitosis in a subset of cancer cells .

HY-144779

HDAC10-IN-1	HDAC Autophagy	Cancer
HDAC10-IN-1 (compound 13b) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 58 nM. HDAC10-IN-1 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-177467

P0064	Apoptosis FLT3	Cancer
P0064 is a selective inhibitor targeting the PR domain of PRDM16. P0064 selectively reduces proliferation and survival of FLT3-ITD+ leukemia cells and induces cell apoptosis. P0064 is promising for research of acute myeloid leukemia (AML) .

HY-144782A

HDAC10-IN-2 hydrochloride	HDAC Autophagy	Cancer
HDAC10-IN-2 hydrochloride (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 hydrochloride modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-10202A

Tandutinib hydrochloride 5 Publications Verification MLN518 hydrochloride; CT53518 hydrochloride	FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the *FLT3* with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier ^[3].

HY-160952

Cytarabine-daunorubicin CPX 351; Daunorubicin-Cytarabine Liposome	Liposome Drug Derivative	Cardiovascular Disease Cancer
Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia .

HY-143286A

PF15 TFA	PROTACs FLT3	Cancer
PF15 TFA is a PROTAC connected by ligands for *FLT3* kinase and CRBN. PF15 TFA is a high selective FLT3-ITD degrader，with a DC50 of 76.7 nM. PF15 TFA significantly inhibits the proliferation of FLT3-ITD-positive cells，can down-regulate the phosphorylation of FLT3 and STAT5. PF15 TFA also inhibits tumor growth in mouse models and can be used in study of leukemia .

HY-148521

PROTAC FLT3/CDK9 degrader-1	CDK FLT3 PROTACs Apoptosis	Cancer
PROTAC FLT3/CDK9 degrader-1 is a potent *FLT3* and CDK9 dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML .

HY-139996

Pomalidomide-C5-Dovitinib	PROTACs Apoptosis FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells. Pomalidomide-C5-Dovitinib induces the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely blocks their downstream signaling pathway. Pomalidomide-C5-Dovitinib has the potential for the research of FLT3-ITD ⁺ acute myeloid leukemia .

HY-145904

*PDGFRα/FLT3-ITD-IN-3*	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of 0.153 and 0.004 μM, respectively. PDGFRα/FLT3-ITD-IN-3 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .

HY-145903

*PDGFRα/FLT3-ITD-IN-2*	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-2 (Compound 13d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of more than 20 and 1.654 μM, respectively. PDGFRα/FLT3-ITD-IN-2 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .

HY-145902

*PDGFRα/FLT3-ITD-IN-1*	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-1 (Compound 12d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of more than 0.036 and 0.003 μM, respectively. PDGFRα/FLT3-ITD-IN-1 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .

HY-144709

FLT3/ITD-IN-1	FLT3	Cancer
FLT3/ITD-IN-1 (Compound 1) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 38.2 nM and 144.1 nM against *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-1 displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-144711

FLT3/ITD-IN-3	FLT3	Cancer
FLT3/ITD-IN-3 (Compound 19) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 0.9 nM against FLT3 ^D835Y, *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-3 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-144710

FLT3/ITD-IN-2	FLT3	Cancer
FLT3/ITD-IN-2 (Compound 17) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 1.0 nM against FLT3 ^D835Y, *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-2 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-160848

FLT3/ITD-IN-5	FLT3	Cancer
FLT3/ITD-IN-5 (Example 6) is an orally active *FLT3* and *FLT3-ITD* inhibitor, with IC₅₀ values of 0.088 and 0.348 nM, respectively. FLT3/ITD-IN-5 can be used for the research of cancer .

HY-146680

FLT3/ITD-IN-4	FLT3 RET CDK MAP4K	Cancer
FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) inhibitor with an IC₅₀ of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research .

HY-168741

FLT3-ITD-IN-2	FLT3	Cancer
FLT3-ITD-IN-2 (Compound A1) is an inhibitor for FLT3-ITD kinase with an IC₅₀ of 2.12 nM. FLT3-ITD-IN-2 inhibits the proliferation of FLT3-dependent human AML cell line MOLM-13 with an IC₅₀ of 25.65 nM. FLT3-ITD-IN-2 exhibits antitumor efficacy against acute myeloid leukemia .

HY-173214

FLT3-ITD-IN-3	FLT3 Apoptosis	Cancer
FLT3-ITD-IN-3 (13v), an orally active FLT3-ITD (FLT3 internal tandem duplication) inhibitor, disrupts *FLT3* signal transduction and induced G0/G1 cell cycle arrest and apoptosis. FLT3-ITD-IN-3 (13v) is used in the research of acute myeloid leukemia (AML) .

HY-158325

*PROTAC FLT-3* degrader 4**	PROTACs FLT3 Apoptosis	Cancer
PROTAC FLT-3 degrader 4 is an orally active CRBN-based *FLT3-PROTAC* degrader that potently induces FLT3-ITD degradation through the ubiquitin-proteasome system. PROTAC FLT-3 degrader 4 shows highly selective to FLT3-ITD mutant acute myeloid leukemia (AML) cells. (Blue: CRBN ligand, Black: linker; Pink: FLT3 inhibitor) .

HY-115443

MZH29	FLT3	Cancer
MZH29 is a potent and orally active *FLT3* inhibitor. MZH29 shows inhibitory effects on wild-type and mutant FLT3, including the FLT3-ITD, FLT3-D835H/Y/V and FLT3-K663Q mutants. MZH29 retains its potent inhibitory effect against the FLT3-ITD/F691L mutation, a drug resistance mutation against the well-known FLT3 inhibitor, AC220 (HY-13001). MZH29 can be used for the research of cancer, such as acute myeloid leukemia (AML) .

HY-161323

FLT3-ITD/D835Y-IN-1	FLT3 Bcr-Abl Apoptosis	Cancer
FLT3-ITD/D835Y-IN-1 (Compound 1) is a *FLT3-ITD* and BCR-ABL inhibitor. FLT3-ITD/D835Y-IN-1 mediates proapoptosis by inhibiting the FLT3 and BCR-ABL pathways, as well as other possible targets. FLT3-ITD/D835Y-IN-1 can be used in the study of acute myeloid leukemia (AML) .

HY-144782

HDAC10-IN-2	HDAC Autophagy	Cancer
HDAC10-IN-2 (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-175273

MA191	PROTACs FLT3 HSP ERK STAT Akt Apoptosis	Cancer
MA191 is a *FLT3* PROTAC degrader. MA191 abrogates *FLT3* inhibitor resistance from rebound activation of mitogen-activated kinases. MA191 mediates rapid *FLT3*-ITD degradation through a mechanism requiring VHL, neddylation, and BIM. MA191 reduces *FLT3*-ITD levels before inducing apoptosis. MA191 halts AML cell proliferation in Danio rerio. MA191 can be used for the study of acute myeloid leukemia (AML) (Pink: FLT3 ligand: (HY-175311), Blue: E3 ligase CRBN Ligand (HY-112078), Black: Linker, E3 ligase ligand-linker conjugate (HY-175312)) .

HY-125008

JH-IX-179	FLT3 Apoptosis	Cancer
JH-IX-179 is an *FLT3* inhibitor (IC₅₀ = 4 nM (FLT3-ITD), 10 nM (FLT3-D835Y)). JH-IX-179 inhibits G1 phase arrest and induces apoptosis in FLT3-ITD-expressing cells. JH-IX-179 can be used in acute myeloid leukemia (AML) research .

HY-143286

PF15	PROTACs FLT3	Cancer
PF15 is a PROTAC connected by ligands for FLT3 kinase and CRBN. PF15 is a high selective *FLT3-ITD* degrader, with a DC₅₀ of 76.7 nM. PF15 significantly inhibits the proliferation of *FLT3-ITD*-positive cells, can down-regulate the phosphorylation of *FLT3* and STAT5. PF15 also inhibits tumor growth in mouse models and can be used in study of leukemia .

HY-179382

HSB401	FLT3 Apoptosis	Cancer
HSB401 is an orally active *FLT3* inhibitor (IC₅₀: 28, 5, 72, 51 nM for FLT3-WT, FLT3-D835Y, FLT3-ITD-F691L, FLT3-ITD, respectively). HSB401 downregulates FLT3 signaling and induces cell cycle arrest and apoptosis. HSB401 spares c-KIT inhibition, thereby reducing the risk of myelosuppression. HSB401 significantly suppresses tumor growth in the MV4-11 xenograft mouse model. HSB401 can be used for the research of acute myeloid leukemia .

HY-E70724

FLT3 ITD Recombinant Human Active Protein Kinase	FLT3	Cancer
FLT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor tyrosine kinase that plays important roles in cell survival, proliferation, and differentiation during normal hematopoiesis. FLT3 is one of the most frequently mutated genes in acute myeloid leukemia (AML). FLT3 ITD is a internal tandem duplication (ITD) mutation of FLT3 that may be present in AML cells. FLT3 ITD Recombinant Human Active Protein Kinase is a recombinant FLT3 ITD protein that can be used to study FLT3 ITD-related functions .

HY-145691

HP1142	FLT3	Cancer
HP1142 is a potent and selective inhibitor of *FLT3* receptor tyrosine kinase (FLT3/ITD mutation). HP1142 is a benzoimidazole scaffold-based compound. HP1142 has the potential for the research of FLT3/ITD leukemia .

HY-155770

FLT3-IN-20	FLT3	Cancer
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor with IC₅₀ values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-20 has anti-proliferation efficacy in FLT3-ITD-positive AML cell lines MV4-11 and MOLM-13 (7 and 9 nM, respectively) and the MOLM-13 variant (4 nM) with the FLT3-ITD-D835Y mutation. FLT3-IN-20 can be used in research of cancer .

HY-145690

HP1328	FLT3	Cancer
HP1328 is a potent inhibitor of *FLT3* receptor tyrosine kinase (FLT3/ITD mutation). HP1328 is a benzoimidazole scaffold-based compound. HP1328 significantly reduces the leukemia burden and prolongs the survival of mice with FLT3/ITD leukemia .

HY-111545

BSc5371	FLT3	Cancer
BSc5371 is a potent and irreversible *FLT3* inhibitor, with K_ds of 1.3, 0.83, 1.5, 5.8 and 2.3 nM for mutant FLT3(D835H), FLT3(ITD, D835V), FLT3(ITD, F691L), FLT3-ITD and wild type FLT3wt, respectively. BSc5371 is cytotoxic to FLT3-dependent cell lines .

HY-160787

NCGC1481	FLT3 IRAK	Cancer
NCGC1481 is an inhibitor of *FLT3, IRAK1, and IRAK4, with IC₅₀* values of <0.5 nM, 22.6 nM, and 0.8 nM, respectively. NCGC1481 can effectively overcome the adaptive resistance of leukemia cells to *FLT3* inhibitors and has antileukemic activity .

HY-170576

FLT3-IN-28	FLT3 STAT Apoptosis	Cancer
FLT3-IN-28 (Compound 12y) is an orally active *FLT3* inhibitor with antitumor activity. FLT3-IN-28 selectively inhibits cancer cells harboring the *FLT3* internal tandem duplication (ITD) mutation, with IC₅₀ values of 85, 290, 130, 65, and 220 nM for BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines respectively (MV4-11 and MOLM-13/14 are acute myeloid leukemia (AML) cell lines carrying the FLT3-ITD mutation). Additionally, FLT3-IN-28 can downregulate the phosphorylation levels of *FLT3* and STAT5 in MOLM-13 cells and induce cell cycle arrest and Apoptosis. FLT3-IN-28 has an oral bioavailability of 19.2% in SD rats and can prolong survival in a dose-dependent manner in NSG mice xenografted with MOLM-13 cells. FLT3-IN-28 holds promise for research in cancer fields related to FLT3-ITD .

HY-116129

BPR1J-340	FLT3 Apoptosis	Cancer
BPR1J-340 is a potent *FLT3* inhibitor with an IC₅₀ of ~25 nM. BPR1J-340 inhibits the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD ⁺ acute myeloid leukemia (AML) cells. BPR1J-340 exhibits significant anti-tumor activities .

HY-162032

FLT3-IN-25	FLT3	Cancer
FLT3-IN-25 (compound 17) is a potent inhibitor of *FLT3, with IC₅₀s of 1.2 nM, 1.4 nM and 1.1 nM for FLT3-WT, FLT3-D835Y* and FLT3-ITD, respectively. FLT3-IN-25 plays an important role in acute myeloid leukemia (AML) .

HY-13001R

Quizartinib (Standard) AC220 (Standard)	Reference Standards FLT3 Apoptosis PDGFR c-Kit	Cancer
Quizartinib (AC220) (Standard) is the analytical standard of Quizartinib (HY-13001). This product is intended for research and analytical applications. Quizartinib is an orally active, potent and selective *FLT3* inhibitor. Quizartinib inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib can be used for the research of cancer .

HY-10202B

Tandutinib sulfate	FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib (MLN518) sulfate is a potent and selective inhibitor of the *FLT3* with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib sulfate can be used for acute myelogenous leukemia (AML) . Tandutinib sulfate has the ability to cross the blood-brain barrier ^[3].

HY-10202AR

Tandutinib hydrochloride (Standard) MLN518 hydrochloride (Standard); CT53518 hydrochloride (Standard)	Reference Standards FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib (hydrochloride) (Standard) is the analytical standard of Tandutinib (hydrochloride). This product is intended for research and analytical applications. Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier ^[3].

HY-10202R

Tandutinib (Standard) MLN518 (Standard); CT53518 (Standard)	Reference Standards FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib (Standard) is the analytical standard of Tandutinib. This product is intended for research and analytical applications. Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier ^[3].

Cat. No.	Product Name		Classification

HY-160952

Cytarabine-daunorubicin CPX 351; Daunorubicin-Cytarabine Liposome		Liposome
Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

FLT3-ITD

Inhibitors & Agonists

NaturalProducts

Oligonucleotides

Natural
Products